Virtus Biotech ETF
BBP
13 hedge funds and large institutions have $5.14M invested in Virtus Biotech ETF in 2024 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 3 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
1.01% more ownership
Funds ownership: 23.44% → 24.45% (+1%)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0% less capital invested
Capital invested by funds: $5.16M → $5.14M (-$19.4K)
7% less funds holding
Funds holding: 14 → 13 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
+$213K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$177K |
| 3 |
LPL Financial
San Diego,
California
|
+$93.8K |
| 4 |
IFG
Independent Financial Group
San Diego,
California
|
+$65.8K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$15.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$210K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$127K |
| 3 |
JCM
Jag Capital Management
St Louis,
Missouri
|
-$30K |
| 4 |
JP Morgan Chase
New York
|
-$6.28K |
| 5 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
-$314 |
BBP Hedge Fund Activity: Q4 2024 in Review
13 of the 7,599 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech ETF (BBP) for Q4 2024, worth a combined $5.14M — down 0.38% from $5.16M a quarter earlier.
Fund positioning in BBP was balanced in Q4 2024: 3 funds opened new positions, 3 closed out, 5 added to existing stakes and 2 trimmed.
The largest buyer was Cetera Investment Advisers, opening a new position worth an estimated $213K. The largest seller was Goldman Sachs, exiting entirely with an estimated $210K sold.
- 13 institutional investors held Virtus Biotech ETF (BBP) as of Q4 2024, down from 14 in Q3 2024.
- Funds reported $5.14M of Virtus Biotech ETF stock for Q4 2024, down 0.38% quarter-over-quarter.
- 3 funds opened new Virtus Biotech ETF positions in Q4 2024 and 3 closed out, a net change of 0 holders.
- The largest Virtus Biotech ETF buyer in Q4 2024 was Cetera Investment Advisers, an estimated $213K added.
- The largest Virtus Biotech ETF seller in Q4 2024 was Goldman Sachs, an estimated $210K sold.
Based on aggregated 13F filings for Q4 2024.